Last reviewed · How we verify
NCT03744858: PYROCVD
The Role of Pyroptosis in Chronic Venous Disease
trial testing Peripheral blood draw in Inflammation in 400 participants. Status unknown.
12 November 2019
Quick facts
| Lead sponsor | University of Catanzaro |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 12 November 2018 |
| Primary completion | 12 November 2019 |
| Estimated completion | 12 November 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Peripheral blood draw
Conditions studied
- Inflammation — all drugs for Inflammation →
- Veins — all drugs for Veins →
- Complication — all drugs for Complication →
- Varicose Veins — all drugs for Varicose Veins →
Sponsor
University of Catanzaro
Who can join
18 and older, any sex, with Inflammation or Veins. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Enrollment criteria and clinical data collection: following the principles of medical ethics, the development of inclusion and exclusion criteria. Selecting 200 cases of chronic venous disease (CVD) according to the Comprehensive Classification System for Chronic Venous Disorders (CEAP) divided into 6 Clinical stages (C1-C6) (Group A). Selecting 200 healthy participants without CVD (C0) as controls (Group B). Blood samples will be collected from both groups. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated between the two groups and between the subgroups, according to clinical stage, in group A.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03744858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Peripheral blood draw
Trials testing the same drug.
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT03988283 — Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors · Phase 1 · recruiting
- NCT03068832 — Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors · Phase 1 · withdrawn
- NCT04643379 — Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and N · Phase 2 · active not recruiting
- NCT04372602 — Duvelisib to Combat COVID-19 · Phase 2 · completed
Other recruiting trials for Inflammation
Currently open trials in the same condition.
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07479940 — Obesity and Aging: Impacts of Nutritional Counseling and Physical Exercise on Telomeres and Senescence Parameters · NA · active not recruiting
- NCT07269847 — Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults · NA · recruiting
- NCT07171450 — Cognitive Remediation · NA · recruiting
- NCT07411612 — The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Pos · recruiting
Other University of Catanzaro trials
Trials by the same sponsor.
- NCT06844552 — Diamagnetic Therapy in Pain and Inflammation · recruiting
- NCT07508969 — Proprioceptive Neuromuscular Facilitation vs Conventional Therapy With Ultrasound-Guided Corticosteroid Injections for S · Phase 1, PHASE2 · completed
- NCT07504432 — Efficacy of Oxygen-ozone Therapy and Cervical Rehabilitation · Phase 1, PHASE2 · completed
- NCT06814769 — Hyaluronic Acid and Articular Pain · completed
- NCT05134597 — Gene Expression in Chronic Venous Leg Ulcers · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03744858 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Catanzaro
- Last refreshed: 16 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03744858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing